MoonLake Immunotherapeutics reported financial results for first quarter of 2026.
“Today, MoonLake also reported its financial results for the first quarter of 2026.”
MoonLake Immunotherapeutics — fact timeline
Source-grounded facts extracted from MoonLake Immunotherapeutics's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
MoonLake Immunotherapeutics incurred term loan of $25.0 million with Hercules Capital, Inc., as administrative agent and collateral agent.
“As described below, after giving effect to a $25.0 million draw on the Amendment Closing Date, the remaining tranches under the Amended Loan and Security Agreement provide for an aggregate principal amount of up to $400.0 million of potential future funding.”
MoonLake Immunotherapeutics amended First Amendment to Loan and Security Agreement (Amended Loan and Security Agreement) with Hercules Capital, Inc. valued at Up to $400.0 million of potential future funding; aggregate principal amount of $500.0 million acros (effective 2026-02-20).
“On February 20, 2026 (the "Amendment Closing Date"), MoonLake Immunotherapeutics (the "Company"), as a guarantor, entered into a first amendment to loan and security agreement (the loan and security agreement, as so amended, the "Amended Loan and Security Agreement") with its subsidiary, MoonLake Immunotherapeutics AG, as borrower, the other guarantors party thereto, the lenders party thereto (the "Lenders"), and Hercules Capital, Inc., as the administrative agent and collateral agent (the "Agent") for itself and the Lenders, pursuant to which the parties agreed to amend the loan and security agreement dated March 31, 2025 to, among other things, modify the available tranches, milestone dates and financial covenants.”
MoonLake Immunotherapeutics reported financial results for the quarter ended March 31, 2024.
“MoonLake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.”
MoonLake Immunotherapeutics reported the quarter and fiscal year ended December 31, 2023 results: net income $44.1 million.
“MoonLake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.